Loading...

NRSN

NRSN

NEUROSENSE THERAPEUTICS LTD

(NRSN)

2024 6-K

Nasdaq Notifications

3 Apr '26

Financial Results Report

31 Mar '26

Regulatory Update

24 Mar '26

Clinical Trial Results

16 Mar '26

Shareholder Meeting

11 Mar '26

Additional Data Released

18 Feb '26

Shareholder Meeting Notice

13 Feb '26

Patent Expansion

9 Feb '26

Shareholder Meeting Results

6 Jan '26

Alzheimer's Study Update

22 Dec '25

Clinical Trial Update

8 Dec '25

Regulatory Update

4 Dec '25

FDA Clearance Update

24 Nov '25

Shareholder Meeting Notice

21 Nov '25

Alzheimer's Drug Update

6 Oct '25

Shareholder Meeting

25 Sep '25

Drug Candidate Update

10 Sep '25

Clinical Data Report

4 Sep '25

Private Placement Update

4 Sep '25

PrimeC ALS Study

2 Sep '25

Annual Meeting Notice

21 Aug '25

Positive ALS Update

20 Aug '25

Business Update

1 Aug '25

Corporate Video Update

10 Jul '25

Regulatory Update

26 Jun '25

Manufacturing Update

7 May '25

Shareholder Update

24 Apr '25

Financial Results Update

7 Apr '25

Pharmaceutical Update

27 Mar '25

PrimeC Progress Report

19 Mar '25

Clinical Trial Results

19 Feb '25

Compliance Regained

6 Jan '25

Binding Term Sheet

23 Dec '24

Business Update Issued

18 Dec '24

Compliance Update

17 Dec '24

FDA Feedback Positive

11 Dec '24

PARADIGM Study Results

4 Dec '24

Private Placement Announcement

2 Dec '24

Nasdaq Compliance Update

12 Nov '24

Equity Purchase Agreement

31 Oct '24

Clinical Trial Update

30 Oct '24

FDA Meeting Secured

28 Oct '24

New Analysis Results

24 Oct '24

ALS Treatment Advancements

15 Oct '24

ALS Treatment Plans

9 Oct '24

Financial Update

30 Sep '24

Company Compliance Update

24 Sep '24

HIPAA Compliance Initiated

16 Sep '24

Study Completion Success

9 Sep '24

Nasdaq Notification

30 Aug '24

Strategic Partnership Talks

28 Aug '24

Nasdaq Compliance Update

26 Aug '24

Sales Agreement Signed

16 Aug '24

Securities Placement

7 Aug '24

Positive Biomarker Data

1 Aug '24

Clinical Trial Success

9 Jul '24

Annual Meeting Results

3 Jul '24

Positive Study Results

1 Jul '24

Warrant Amendments

27 Jun '24

Corporate Update Issued

24 Jun '24

Delisting Notice

21 Jun '24

Accounting Method Change

17 Jun '24

Annual Meeting Notice

28 May '24

Annual Meeting Notice

23 May '24

R&D Participation

20 May '24

Partnership Announcement

14 May '24

Positive Trial Results

7 May '24

Securities Offering

12 Apr '24

Business Update

10 Apr '24

Collaboration Announcement

9 Apr '24

Financial Results Update

5 Apr '24

Company Update

22 Feb '24

Compliance Regained

7 Feb '24

Positive ALS Progress

9 Jan '24

Business Update

9 Jan '24

External Links:

SEC

On November 11, 2024, NeuroSense Therapeutics Ltd. received confirmation to continue its Nasdaq listing, contingent on filing compliance documentation by December 18, 2024, after previously falling below the $2,500,000 equity requirement.

AI Assistant

NEUROSENSE THERAPEUTICS LTD

2024

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.